ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Bio-Thera Solutions Ltd. engages in the research, development, and production of innovative drugs and biosimilar drugs for the treatment of tumours, autoimmune diseases, cardiovascular diseases, other threats to human life, and major health diseases. The company was founded by Sheng Feng Li on July 28, 2003 and is headquartered in Guangzhou, China.

Part of Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai Jiaolian Drug Development Co. Ltd. is a Chinese company located in Shanghai that develops pharmaceutical products. On December 02, 2013 Shanghai Pharmaceuticals Holding Co., Ltd. acquired Shanghai Jiaolian Drug Development Co. Ltd. for $1.64 million.

MicroBioPharm Japan Co. Ltd. manufactures pharmaceutical drugs and chemicals, and drug discovery business. It products include Anthracycline analogues, Macrolide analogue, Calcitriol, Paricalcitol and Cyclodextrins. The firm offers toll fermentation, contract research, seed discovery support and drug discovery support services. It partners with pharmaceuticals companies and external research institutes. The company was founded on July 1, 2011 and is headquartered in Tokyo, Japan.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Suzhou Kangju Biotechnology Co., Ltd., established on 2011-08-15, Business scope includes biomedical technology research and development,technical consulting,technology transfer,Technical Services;Sales:Biochemical reagents,Pharmaceutical Intermediates,Experimental Consumables;Engaged in the export of the company's self-developed products and pharmaceutical intermediates,Import business of experimental reagents and consumables.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:pharmaceutical production;Pharmaceutical commissioned production;Drug import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Liaoning Swell Biotechnology Co., Ltd., established on 2013-07-15, The scope of business includes research on bioengineering and biological products,to develop,Production(Branch operation),Sales,technology transfer;Technical development of raw materials for biological products,technology transfer;Chinese herbal medicine planting(Branch operation);New product development of Chinese herbal medicine,technology transfer;laboratory equipment,Instrumentation,Electrical Equipment,communication device,HVAC equipment,plumbing equipment,building decoration materials,furniture sales;Laboratory equipment installation,repair,lease(In addition to exclusive control);Indoor and outdoor decoration project,Environmental Engineering Design,construction;Electromechanical equipment technology development,technology transfer,Technical Advisory Services;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany.

Smithkline Beecham Ltd. manufacture of basic pharmaceutical products. It also provides mineral water, bottled water, and soft drinks. The company was founded on January 24, 1989 and is headquartered in Brentford, the United Kingdom.

Shanghai Jianhe Pharmaceutical Technology Co., Ltd., established on 2015-04-13, Business scope includes pharmaceuticals,Research and development of fine chemicals,Pharmaceutical Intermediates(except medicines)promotion of,Engaged in the import and export of goods and technology,And provide technical development in the above related fields,technical consulting,technology transfer,Technical Services. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Siemens AG is a technology company, which engages in the areas of automation and digitalization in the process and manufacturing industries, infrastructure for buildings and energy systems, mobility solutions for rail transport, and medical technology and digital healthcare services. It operates through the following segments: Digital Industries, Smart Infrastructure, Mobility, Siemens Healthineers, and Siemens Financial Services. The Digital Industries segment offers a product portfolio and system solutions for automation used in discrete and process industries. The Smart Infrastructure segment includes products, systems, solutions, services and software to support a transition from fossil to renewable energy sources. The Mobility segment combines all Siemens businesses in the area of passenger and freight transportation. The Siemens Healthineers segment develops, manufactures, and sells diagnostic and therapeutic products, and services to healthcare providers. The Siemens Financial Services segment focuses on financing solutions for Siemens’ customers as well as other companies in the form of debt and equity investments. The company was founded by Johann Georg Halske and Werner von Siemens on October 12, 1847 and is headquartered in Munich, Germany.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.